Red5 Pharmaceuticals, LLC is an emerging start-up company based in Cleveland, Ohio focusing on the development of innovative therapeutic agents against cancer. Our company performs the chemical synthesis and pharmaceutical testing of non-natural nucleosides as novel anti-cancer agents against hematological cancers and solid tumors. Red5 Pharmaceuticals, LLC currently leverages its patented technology in three biomedical areas described below:
Developing non-natural nucleosides as adjunctive therapeutic agents that enhance the anti-cancer effects of existing chemotherapeutic agents. We have demonstrated that several of our analogs significantly increase the efficacy and potency of anti-cancer agents such as temozolomide, cisplatin, and carmustine.
2. Theranostic Agents
The development and application of non-natural nucleosides as “personalized medicines” against cancer. Primary therapeutic targets include acute lymphoblastic leukemia (ALL), Merkel cell carcinoma, and glioblastoma.
3. Diagnostic Detection of Pro-Mutagenic Replication
Using non-natural nucleotides as mechanistic probes to study the replication of damaged DNA. One goal is to detect the misreplication of specific pro-mutagenic DNA lesions in bacterial, viral, and human cells. Other applications include the use of these nucleotide anologs to PCR amplify genomic DNA containing various DNA lesions.